InnoCare shares rise more than 4% as nine-month results turn profitable
InnoCare Therapeutics rose more than 4% intraday. The company turned profitable in the first three quarters, while sales of orelabrutinib increased.
Related stories
Kyoei Steel Reports Six-Month Group Net Profit; Forecasts Lower 2026/27 Profit
Kyoei Steel reported six-month group net profit and provided its 2026/27 profit forecast.
M impact | EARNINGS | Oct 30, 2026, 04:03 AM UTC
Nova System Reports Nine-Month Parent Recurring Profit
Parent recurring profit rose 149.3%; the company forecasts 2026 profit up 81.6%.
L impact | EARNINGS | Oct 30, 2026, 04:03 AM UTC
LIXIL Reports Interim Operating Profit Down 44.1%
LIXIL reported consolidated interim operating profit of 63.74億円, down 44.1%. It forecasts operating profit of 375.00億円 for the fiscal year, up 32.0%.
M impact | EARNINGS | Oct 30, 2026, 04:03 AM UTC
Nova System Reports Nine-Month Parent Operating Profit of 434 Million Yen
Operating profit rose 170.4%. The company forecasts 2026 profit of 617 million yen, up 90.3%.
M impact | EARNINGS | Oct 30, 2026, 04:03 AM UTC
LIXIL Reports Six-Month Group Net Loss
LIXIL reported a six-month IFRS group net loss versus a profit in the prior-year period. It forecasts 2026/27 profit, up 47.4%.
M impact | EARNINGS | Oct 30, 2026, 04:03 AM UTC
Kyoei Steel Reports Half-Year Ordinary Profit Down 30.1%, Forecast Down 44.5%
Kyoei Steel reported consolidated ordinary profit down 30.1% for the half-year period and forecasts ordinary profit down 44.5% for the fiscal year ending in March.
M impact | EARNINGS | Oct 30, 2026, 04:03 AM UTC